Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNidhi KejriwalAYAustin YangMAMojtaba Akhtari

Discussion

Loading...

Member takes

Overview

Systematic review reports high overall response and complete response rates in R/R large B-cell lymphoma, suggesting promising efficacy for CAR T-cell therapy.

Key Points

  • To characterize the efficacy and safety of lisocabtagene maraleucel monotherapy in treating relapsed or refractory large B-cell lymphoma.
  • Followed PRISMA guidelines for systematic review and meta-analysis.
  • Included 11 studies comprising five clinical trials and six real-world studies with 1206 patients.
  • Utilized random-effects model for meta-analyses and assessed heterogeneity using I2 statistic.
  • Pooled overall response rate was 78% with 95% confidence interval of 73%-82%.
  • Complete response rate was 60% with confidence interval 55%-66%.
  • Mortality due to adverse events was low at 4%, with cytokine release syndrome and neurotoxicity rare.

Cite This Study

Kejriwal et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8f6https://doi.org/10.1182/blood-2025-7232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies2026
  2. 2Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.2026
  3. 3Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma2026 · 3 citations
  4. 4Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.2026
  5. 5Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry2025